

# New Cellulite Therapies Target Fibrous Septae


BY BRUCE JANCIN

EXPERT ANALYSIS FROM THE SDEF HAWAII DERMATOLOGY SEMINAR

WAIKOLOA, HAWAII – Cellulite therapy may be moving out of the dark ages of overhyped claims made on behalf of interventions of little or no value to an era of treatments that work.

And what appears to work, according to Dr. Michael S. Kaminer, are therapies that cut the fibrous septae tethering the dermis to deeper tissues.

"I think it's likely that the vertical pull



BRUCE JANCIN/MEDICAL MEDIA

**"Until very recently, there was absolutely no reason to pay attention to cellulite," Dr. Michael S. Kaminer said at the seminar.**

of the fibrous septae tends to pull down on the cellulite in the skin and causes the cellulite dimples," he explained at the seminar sponsored by Skin Disease Education Foundation (SDEF).

The fibrous septae theory of the etiology of cellulite is relatively new. It has gained substantial credence as a result of encouraging clinical trial data showing long-term effectiveness for two devices targeting cellulite via severing fibrous septae: the Cellulaze 1,440-nm Nd:YAG laser and the Cabochon Aesthetics controlled subcision system for subdermal undermining, according to Dr. Kaminer, who is a managing partner at Skin-Care Physicians, Chestnut Hill, Mass.

Cellulaze, developed by Cynosure, recently received Food and Drug Administration marketing approval for the treatment of cellulite. The Cabochon device for subcutaneous release of fibrous septae is still in clinical trials.

"Until very recently, there was absolutely no reason to pay attention to cellulite except to counsel patients as to the fact that they shouldn't waste their money," Dr. Kaminer said.

The situation has changed with the emergence of fibrous septae as the prime therapeutic target. Cellulaze can be used for laser lipolysis; however, in addition, the handpiece for the cannula can be turned in such a way that the laser beam can be used like a saw to cut through the fibrous septae, with resultant long-term improvement in cellulite.

In U.S. clinical trials, the average in-

crease in skin thickness following Cellulaze therapy was 23% at 1 month and 27% at 1 year. Skin elasticity improved over baseline by 32.5% at 1 month and 21% at 1 year. Sixty-eight percent of patients demonstrated significant improvement in cellulite based upon analysis of photographs, as did 65% when assessed by Vectra 3D surface imaging.

Patients rated the results as good to excellent at 1 month in 76% of cases. Physicians judged the results as good to excellent in 69% of cases. The results have held up at 1 year of follow-up, noted Dr.

Kaminer, who also is with the dermatology departments of Yale University, New Haven, Conn.; Dartmouth College, Hanover, N.H.; and Brown University, Providence, R.I.

The downside of Cellulaze is that it is an invasive therapy that requires tumescent anesthesia. And given that the history of the field of cellulite therapy is one of hype far in excess of reality, Dr. Kaminer indicated that a healthy skepticism is appropriate. "For me, I'm going to approach this with caution. ... I'd like to see it around for a little longer before we all jump on the bandwagon."

The Cabochon system draws a small section of skin affected by cellulite into a handpiece so that a percutaneously inserted cutting tool can be utilized to cut the fi-

brous septae. Dr. Kaminer was an investigator in a two-site, 56-patient clinical trial with a 6- to 12-month follow-up.

In independent blinded physician review of before and after photos, 78% of patients were judged to have improved at least one full grade in severity at 6 months, such that, for example, those whose cellulite was rated severe at baseline were judged to have moderate or mild cellulite at follow-up.

At baseline, the average cellulite severity score was about 4.5 on a 0-6 scale. At 90 days, the average severity score had dropped to 3, and at 180 days to roughly 2.5. Ninety-four percent of patients were rated by independent physicians as having improved by at least 1 point on the 0-6 scale. Of the 33 U.S. patients followed for 1 year, 87% felt their appearance was improved and 77% were satisfied with their treatment at all time points.

Seroma formation was an issue early on, until investigators realized the problem resulted from treating adjacent sites at the same depth. But once operators began utilizing the device's automated guidance system to vary the cutting depth at adjacent sites seromas were no longer a problem. None of 25 patients treated in this fashion had a seroma in excess of 2 cc 1 month post treatment, said Dr. Kaminer.

He reported serving as a consultant to Cabochon and receiving funding from Cynosure. SDEF and this news organization are owned by Elsevier. ■

WHEN PATIENTS NEED MORE!

**KENALOG®  
SPRAY 100 g  
Triamcinolone Acetonide  
Topical Aerosol, USP**

**0.2%\* Triamcinolone**



For dermatological use only. Not for ophthalmic use.

63 g Still Available!

\*After spraying, the nonvolatile vehicle remaining on the skin contains approximately 0.2% triamcinolone acetonide. Each gram of spray provides 0.147 mg triamcinolone acetonide in a vehicle of isopropyl palmitate, dehydrated alcohol (10.3%), and isobutane propellant.

| Product Description | Unit Size | NDC          | McKesson Stocking # | Cardinal Stocking # | ABC Stocking # |
|---------------------|-----------|--------------|---------------------|---------------------|----------------|
| Kenalog® Spray      | 100 g     | 10631-093-07 | 1938711             | 4523379             | 138798         |
| Kenalog® Spray      | 63 g      | 10631-093-62 | 2538924             | 4226635             | 064642         |

**PRECAUTIONS**  
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Use as directed. Refer to full Prescribing Information. For more information go to [www.kenalogspray.com](http://www.kenalogspray.com)

**RANBAXY**

DERM-2918-0212

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).